0001209191-23-018191.txt : 20230313
0001209191-23-018191.hdr.sgml : 20230313
20230313163141
ACCESSION NUMBER: 0001209191-23-018191
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230310
FILED AS OF DATE: 20230313
DATE AS OF CHANGE: 20230313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAU JOHNSON YIU NAM
CENTRAL INDEX KEY: 0001181165
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38112
FILM NUMBER: 23727734
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athenex, Inc.
CENTRAL INDEX KEY: 0001300699
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 431985966
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
BUSINESS PHONE: 716-898-8625
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20131223
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC
DATE OF NAME CHANGE: 20040817
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-10
0
0001300699
Athenex, Inc.
ATNX
0001181165
LAU JOHNSON YIU NAM
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600
BUFFALO
NY
14203
1
1
0
0
CEO and Chairman of the Board
Common Stock
2023-03-10
4
A
0
5519
1.94
A
215734
D
Common Stock
33944
I
By Avalon Biomedical (Management) Limited
Common Stock
8247
I
By Spouse
Common Stock
5360
I
By Avalon Polytom (HK) Limited
Stock Option (Right to Buy)
150.00
2018-05-22
2025-05-22
Common Stock
70000
70000
D
Stock Option (Right to Buy)
220.00
2018-06-13
2027-06-13
Common Stock
1
1
D
Stock Option (Right to Buy)
180.00
2019-07-17
2025-07-17
Common Stock
2746
2746
I
By Avalon Biomedical (Management) Limited
Stock Option (Right to Buy)
346.00
2022-03-27
2028-03-27
Common Stock
12500
12500
D
Stock Option (Right to Buy)
263.40
2023-02-28
2029-02-28
Common Stock
12500
12500
D
Stock Option (Right to Buy)
146.40
2020-12-31
2030-03-24
Common Stock
2753
2753
D
Stock Option (Right to Buy)
249.00
2030-06-05
Common Stock
15000
15000
D
Stock Option (Right to Buy)
76.00
2031-08-03
Common Stock
7500
7500
D
Restricted Stock Units
Common Stock
5625
5625
D
Stock Option (Right to Buy)
13.31
2032-07-20
Common Stock
12500
12500
D
Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Dr. Johnson Lau ("Dr. Lau") owns all of the outstanding interests in Creative Decade Global Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Lau serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
Dr. Lau disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Lau is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
This option vests in four equal annual installments beginning on June 5, 2021.
This option vests in four equal annual installments beginning on August 3, 2022.
Each restricted stock unit represents a contingent right to receive one share of stock.
The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
This option vests in four equal annual installments beginning on July 20, 2023.
/s/Steven Adams, Attorney-in-Fact
2023-03-13